Title : Repurposing dextromethorphan and metformin for treating nicotine-induced cancer by directly targeting CHRNA7 to inhibit JAK2/STAT3/SOX2 signaling.

Pub. Date : 2021 Mar

PMID : 33603170






4 Functional Relationships(s)
Download
Sentence
Compound Name
Protein Name
Organism
1 Here we report that nicotine enhances ESCC cancer malignancy and tumor-initiating capacity by interacting with cholinergic receptor nicotinic alpha 7 subunit (CHRNA7) and subsequently activating the JAK2/STAT3 signaling pathway. Nicotine cholinergic receptor, nicotinic, alpha polypeptide 7 Mus musculus
2 Mechanistically, dextromethorphan non-competitively inhibited nicotine binding to CHRNA7 while metformin downregulated CHRNA7 expression by antagonizing nicotine-induced promoter DNA hypomethylation of CHRNA7. Nicotine cholinergic receptor, nicotinic, alpha polypeptide 7 Mus musculus
3 Mechanistically, dextromethorphan non-competitively inhibited nicotine binding to CHRNA7 while metformin downregulated CHRNA7 expression by antagonizing nicotine-induced promoter DNA hypomethylation of CHRNA7. Nicotine cholinergic receptor, nicotinic, alpha polypeptide 7 Mus musculus
4 Mechanistically, dextromethorphan non-competitively inhibited nicotine binding to CHRNA7 while metformin downregulated CHRNA7 expression by antagonizing nicotine-induced promoter DNA hypomethylation of CHRNA7. Nicotine cholinergic receptor, nicotinic, alpha polypeptide 7 Mus musculus